Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01882504 · ClinicalTrials.gov registry record · Phase 2
Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum
A Phase 2 study of Pyoderma Gangrenosum, sponsored by Xoma (US).
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 19
- Study locations
NCT01882504 is a Phase 2 study of Pyoderma Gangrenosum that has completed, run by Xoma (US). The registered enrollment target is 8 participants, below the 37-participant average among 3 other Pyoderma Gangrenosum trials with a reported enrollment target (78% lower). The trial reports 19 study locations across 15 states.
The verdict
NCT01882504, a Phase 2 study of Pyoderma Gangrenosum, has completed, sponsored by Xoma (US).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 19
- Study locations
Study Summary
The study will evaluate the safety and biologic activity of gevokizumab in subjects in the acute inflammatory phase of pyoderma gangrenosum.
Conditions Studied
Interventions
- DRUG gevokizumab
Study Locations (19)
Texas
- - Arlington
- - Dallas
- - Houston
Florida
- - Miami
- - Miami Shores
Ohio
- - Cleveland
- - Columbus
Alabama
- - Birmingham
Illinois
- - Chicago
Maryland
- - Baltimore
Michigan
- - Ann Arbor
Minnesota
- - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01882504
The ClinicalTrials.gov registry entry for NCT01882504 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 37-participant average among 3 other Pyoderma Gangrenosum trials with a reported enrollment target (78% lower). The listed sponsor is Xoma (US), which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pyoderma Gangrenosum appearing as the primary indexed condition, and to 1 intervention - of which gevokizumab is the first listed.
NCT01882504 reports 19 study locations spanning 15 distinct geographic areas - top geographies include Texas, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT01882504 about?
NCT01882504 is a clinical study titled "Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum". The study will evaluate the safety and biologic activity of gevokizumab in subjects in the acute inflammatory phase of pyoderma gangrenosum.
What is the current status of trial NCT01882504?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2013-05. Estimated completion is 2015-10.
What conditions does trial NCT01882504 study?
This clinical trial studies the following conditions: Pyoderma Gangrenosum.
What interventions are being tested in trial NCT01882504?
The interventions under investigation include: gevokizumab (DRUG).
Who is sponsoring clinical trial NCT01882504?
This trial is sponsored by Xoma (US), which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01882504 being conducted?
This trial has 19 study locations across Alabama, Florida, Illinois, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pyoderma Gangrenosum
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.